Beginning to implement FPM’s Strategy 2026–28: a professional home in changing times
Posted on: Monday 2 February 2026
As we begin to implement FPM’s Strategy for 2026–28, it feels like a good moment to pause and reflect – not just on where FPM is heading, but on where we, as pharmaceutical physicians, find ourselves right now.
For many members, uncertainty is no longer abstract. It shows up in changing roles, evolving expectations, portfolio careers, and questions about professional identity. Whether you work in industry, regulation, academia, clinical practice, or across several of these, the ground beneath pharmaceutical medicine is shifting – scientifically, organisationally, and culturally.
At its heart, FPM exists for a clear purpose: to advance pharmaceutical medicine for the benefit of patients and the public. The work our members do – across medicines, vaccines, medical devices, diagnostics, precision therapies, genomics and digital health – has never been more important. But the context in which that work happens has become more complex.
Pharmaceutical Medicine in a changing landscape
As members will recognise, pharmaceutical medicine sits at the intersection of innovation, regulation, ethics, and patient safety. Our specialty exists because history taught us that medical innovation cannot rely on goodwill or general training alone – it requires specialist expertise, professional standards, and strong governance across the entire lifecycle of medical products.
What feels different now is the pace and breadth of change. Rapid scientific advances, increasing public scrutiny, geopolitical uncertainty, and organisational restructuring are reshaping how many of us work. Alongside this, patients and the public are increasingly accessing health information from unregulated and unchecked sources, particularly through social media platforms and generative technologies.
While these tools can offer accessibility and engagement, they also carry significant risks – from the spread of misinformation and disinformation, to the erosion of trust in evidence-based medicine. Many members are already encountering the consequences of this in their professional lives, whether through patient feedback, policy challenges, or public debate.
This evolving information landscape reinforces the importance of pharmaceutical medicine as a discipline grounded in evidence, ethics, and public responsibility – and highlights the role FPM can play in supporting members to navigate, challenge, and respond to misinformation with confidence and authority.
Why a refreshed strategy matters now
The Strategy for 2026–28 is not an abstract exercise. It is a direct response to themes that emerged repeatedly through Board discussions, member feedback, and survey responses – particularly the sense of uncertainty many members are navigating.
The Board undertook a comprehensive strategy development process with a clear aim: to ensure FPM remains relevant, responsive, and genuinely supportive of its members, while continuing to champion the specialty and its contribution to public health.
The resulting strategy sets a clear direction for how FPM will strengthen its support for both members and the discipline over the next three years.
Our strategic vision and four pillars
The strategy is built around a simple but important commitment: that every pharmaceutical physician should have a professional home that recognises their expertise, strengthens their professional identity, and equips them to advance health responsibly.
To deliver this, FPM’s work will be focused through four strategic pillars:
- Strengthening professional identity
- Extending reach and influence
- Supporting ideation and innovation
- Ensuring strong governance and organisational resilience
Together, these pillars reflect what matters most to our community and provide a practical framework for action.
What this means for you as a member
Being a professional home means more than offering services. It means being present for members throughout their careers and across the changes shaping our specialty.
In practical terms, the strategy focuses on helping members feel:
- More confident in practising pharmaceutical medicine, through education, training, and continuing professional development
- More connected, through mentoring, networks, and peer support
- Better equipped to engage with complex public and policy conversations, including those shaped by misinformation and emerging technologies
As the strategy is implemented, you will begin to see these commitments translated into tangible activity – from enhanced membership support and influence campaigns to innovation forums and governance improvements.
A renewed focus on membership
One of the first major pieces of work under the new strategy is a comprehensive membership project. This will review membership categories, routes to membership, and benefits, as well as how we support members at different career stages and in different professional contexts, both in the UK and internationally.
The aim is straightforward: to strengthen professional identity, increase value for members, and ensure that FPM genuinely feels like a professional home for pharmaceutical physicians – wherever and however they practise.
A shared journey forward
Our profession has evolved significantly since FPM was established. What once focused primarily on new medicines now spans a much wider landscape of technologies and approaches, all united by the same fundamental responsibility: to support safety, effectiveness, ethical use, and public trust.
In a world where change and uncertainty are constant, FPM’s mission remains steadfast – to advance pharmaceutical medicine for the benefit of patients and the public. As we begin to implement the Strategy for 2026–28, that mission will guide everything we do, with our members firmly at the heart of it.